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The phenomenon of pain may be neuropathic in nature 
and it invariably stems from disease or injury affecting the 
somatosensory system (1,2). Neuropathic pain is usually a 
chronic condition and is a significant cause of morbidity. 
It has a pronounced impact on wellbeing as well as patient 
quality of life and of those patients presenting with pain, 
up to a quarter of them suffer neuropathic pain (3,4). It 
involves symptoms of an abnormally unpleasant sensation 
(dysesthesia), allodynia typified by a painful sensation to a 
normally innocuous stimulus and hyperalgesia characterized 
by an exaggerated pain perception to a normally noxious 
stimulus (5). 
Hyperalgesia ensues from aberrant nociceptor input 
processing, whereas allodynia can be evoked by activity of 
low threshold myelinated Aβ nerve fibres on a perturbed 
central nervous system and also a diminished threshold 
of peripheral nociceptor terminals (1). In this context, 
damage to peripheral nerves can lead to dysfunctional 
adaptation at different locations in the pain pathway and 
substantial changes in the central nervous system take 
place as a consequence. Hence, it has been deduced that 
central sensitization may behave as an amplifier of incoming 
peripheral neuronal information (6). More recently, 
studies on behaviour in relation to gene expression in the 
partial nerve injury model have revealed that two separate 
processes may be implicated in neuropathic pain. Thus, 
cold sensitive allodynia may develop in neurons, while an 
additional process including both neurons and immune cells 
instigates tactile allodynia (7). 
The mechanisms underlying neuropathic pain and 
the experience of pain in general are far from complete 
in terms of understanding, though studies in humans 
and animal models have made a major contribution to 
this field. However, progress in this area of research has 
been hindered by innate translational problems firstly, in 
examining neuronal processes in humans; secondly, from 
changes in nociceptors brought about by invasive study 
methods; thirdly, because of the current inadequacy of 
existing techniques to record from microscopic structures 
involved in transduction of noxious stimuli; fourthly, due to 
the uncertainty that available animal models authentically 
reflect the perception of pain (8).
A selection of induced neuropathic pain models (9) and 
some subsequent common pain outcome measures (10) are 
shown in Table 1. In this connection, it has been noted that 
pain treatments targeting explicit pain mechanisms, tend to 
be more effective than disease/cause-based treatments which 
may be less specific. This may explain why many effective 
drugs in preclinical research fail in clinical trials (11). Also, 
the time course of pain development in animal neuropathic 
models and the duration of outcome assessments is inclined 
to be much shorter than that observed either in clinical trials 
or in clinical practice (11). These are important matters in 
extrapolating from bench to clinic. However, it should be 
kept in mind that among small endothermic animals such 
as rodents, the surface-to-volume ratio and basal metabolic 
rate are both greater than humans. In addition, in these 
smaller mammals, not only is the overall life span shorter, 
but cellular membranes are more polyunsaturated than 
larger species. Hence, there is a body size related variation 
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in the membrane docosahexaenoic acid (DHA) content (12). 
Consequently, when considering the timeframe differences 
between studies with neuropathic models and clinical 
research, it is worthwhile bearing in mind these potentially 
influential allometric and biochemical factors.
Tissue and nerve damage lead to inflammation and 
initiation of repair processes triggering the condition 
of peripheral sensitization which is characterized by 
hyperexcitability and this usually subsides in the short-term 
upon healing. However, if the process of cellular insult is 
continuous as the result of a disease like diabetes, this state 
may be long lasting (11). In consequence, a neuropathic 
pain model based on this principle may prove to be 
useful. In view of this, the diabetic neuropathy model was 
developed (13). 
In the same theme, longer-term neuropathic pain models 
such as chronic sciatic nerve constriction injury (14) and 
chemotherapy-induced peripheral neuropathy (15,16) have 
proved useful in assessing potential activity versus neuropathic-
like pain. Similarly, a number of diabetic neuropathic 
pain studies have been carried out using the diabetogenic 
β-pancreatic islet cell toxin streptozotocin (13). This 
technique has even been shown to be valuable in detecting 
activity of a drug-containing topical gel preparation 
not only against neuropathic-like allodynia but also 
vulvodynia (17,18) and it has led to the prediction of clinical 
effectiveness (19). However, streptozotocin produces intense 
type 1 diabetic insulinopenia and hyperglycemia and because 
the type 2 form is more prevalent, this facet warrants 
further detailed examination. Moreover, the neuropathy 
incited by the two diabetic forms is fundamentally different 
since for example, strict glucose control has much higher 
efficacy in preventing type 1 rather than type 2 diabetic 
neuropathy (20). Consequently, a reliable neuropathic 
model for type 2 diabetes is exceptionally timely.
Recently, streptozotocin-induced experimental diabetes 
has been produced in neonatal rats (nSTZ) and it was 
demonstrated that in addition to glucose intolerance, the 
hyperglycemia induced in these animals was much milder 
than in adults (21). Also, C-fibre nerve conduction velocity 
in nSTZ animals was reduced in a similar fashion to adults, 
but it occurred considerably later in neonates following 
treatment with streptozotocin. In nSTZ animals, there was 
also a delayed augmentation of activated transcription factor 
3 (ATF3) immunoreactivity in the spinal cord and the dorsal 
root ganglia (DRG) which correlated with an upregulation 
of both ATF3 and glial fibrillary acidic protein (GFAP). 
ATF3 is regarded as a marker of regeneration after injury in 
DRG neurons and GFAP is expressed by cells such as glial 
astrocytes in the central nervous system. It was reasonably 
suggested therefore that satellite glial cells, microglia 
and astrocytes are activated in the DRG and spinal cord 
following neonatal treatment with streptozotocin. It is 
Table 1 A selection of induced neuropathic pain models (9) and 
some more common examples of nociceptive outcome measures (10)
Models and measures Examples




Chronic sciatic nerve constriction
Partial sciatic nerve ligation
Spinal root ligation
Spared nerve injury








Trigeminal neuralgia (trigeminal nerve 
ganglion agar injection)





Hargreaves (control and test in the same 
subject)
Acetone-induced cold stimulus









Place escape avoidance paradigm
Behavioral function Eating, drinking, posture, gait, grooming, 
social interaction, general activity
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noteworthy that all these characteristics were attended 
by tactile allodynia to von Frey filament application, 
substantiating the notion that nSTZ causes nerve injury. 
The nSTZ diabetic model has been designated as one which 
mimics type 2 diabetes (22), although more recent authors 
acknowledged that their findings did not fully support this 
overall postulation (21). Nevertheless, nSTZ did disclose 
some of the features of type 2 diabetes and the animals in 
the nSTZ model were much healthier than those in the type 
1 diabetic model (STZ in adult animals). Consequently, 
the nSTZ model has been posited as a suitable choice for 
investigating diabetic neuropathic pain (21).
In the clinic, neuropathic pain of a spontaneous kind is 
undoubtedly more commonplace and distressing than the 
induced pain that is frequently measured as a neuropathic 
model outcome. In this respect, it has not been established 
whether induced pain in preclinical studies is accompanied 
by the perception of spontaneous pain in animals. Another 
confounding factor from a translational point of view, is that 
evoked pain outcome measures can account for the sensory-
discriminative element of pain often represented by ratings 
of intensity. However, they do not take into consideration 
the affective component of pain. This has been described as 
a characteristic reaction to a noxious stimulus heralded by 
an initial affective-motivational response sometimes termed 
“pain unpleasantness”. A second affective stage, concomitant 
with longer-term pain involves intricate emotional 
consequences such as depression (23). It is evident therefore 
that pain outcome measures for useful neuropathic models 
such as nSTZ should mimic spontaneous pain which may 
have closer relevance to clinical practice (11). Current 
inclinations for pain assessment in neuropathic models 
have focused on more non-reflexive outcome measures 
in attempts to evaluate pain rather than nociceptive 
reflexes (24). Accordingly, the provision of animal locational 
choice may be employed, as in conditioned place aversion 
to noxious stimuli, or conditioned place preference to 
signify pain relief, although this latter paradigm may also 
manifest reward. Animal facial coding scales have been 
developed using an orbital tightening score to reflect the 
facial expression of pain level and vocalization has also 
been used to indicate an acute emotional aspect of pain. 
Other parameters such as cognitive function, sleep pattern, 
autonomic function and social interaction have also been 
studied from the perspective of chronic pain (24). 
In the case of the nSTZ paradigm mentioned earlier, 
the generated tactile allodynia (associated with mild 
hyperglycemia, glucose intolerance, and glial cell 
activation) was relieved by gabapentin, metformin and 
morphine indicating the presence of neuropathic-like 
pain (21). Ostensibly, this model may well have translational 
value, though in consideration of the foregoing discussion, 
the model outcome measure that was employed, involved 
evoked pain rather than an affective component evaluation. 
This emphasizes the duality of translational challenges 
coupled to neuropathic models and their outcome measures, 
so clinically, not only does neuropathic pain remain 
refractory to treatment but also difficult to replicate and 
evaluate.
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